Want to see AU:CYC full AI Analyst Report?
CYC Stock Chart & Stats
AU$0.52
-AU$0.02(-3.57%)
At close: 4:00 PM EDT
AU$0.52
-AU$0.02(-3.57%)
Day’s Range― - ―
52-Week RangeAU$0.45 - AU$1.29
Previous CloseN/A
Volume5.87K
Average Volume (3M)54.10K
Market Cap
AU$64.12M
Enterprise ValueAU$51.92
Total Cash (Recent Filing)AU$12.25M
Total Debt (Recent Filing)AU$7.80M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding125,734,146
10 Day Avg. Volume53,947
30 Day Avg. Volume54,101
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside92.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)AU$36.60M
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSustained top-line growth indicates continued commercial traction for Technegas and related products. If maintained, expanding usage and market access can support a larger installed base and recurring consumables revenue.
Recurring Consumables ModelConsumables linked to an installed generator base can create repeat purchasing and greater revenue visibility than equipment sales alone. Wider adoption therefore has the potential to build a durable annuity-like revenue stream.
Meaningful Equity BaseA meaningful equity base gives Cyclopharm some capacity to fund operations and pursue its commercial strategy while losses continue. This buffer may reduce immediate balance-sheet fragility, although it does not remove future funding risk.
Bears Say
Deteriorating ProfitabilityNegative gross profit means costs exceeded revenue at the gross level, weakening the economics of the current business. Persistent losses could limit reinvestment, require additional funding and undermine the benefits of otherwise steady revenue growth.
Heavy Cash BurnDeeply negative operating and free cash flow shows that commercial activity is not yet self-funding. Continued cash consumption raises dependence on external capital and leaves less flexibility to invest in product expansion or absorb execution setbacks.
Rising Leverage And Balance-Sheet PressureHigher debt alongside shrinking equity increases financial risk and may raise repayment or refinancing pressure. Declining assets also suggest balance-sheet erosion, reducing flexibility if losses and cash requirements remain elevated.
Cyclopharm Limited News
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$0.45 and its highest was AU$1.29 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$64.12M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Feb 24, 2027 which is in 173 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Aug 23, 2026. The company reported -AU$0.073 earnings per share for the quarter.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Undervalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 125,734,146 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.073 in its last earnings report. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cyclopharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (92.31% Upside)
AU$1.00 (92.31% Upside)
Blogger Sentiment
Bullish
AU:CYC Sentiment 80%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.15%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cyclopharm Limited
Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business activities are structured into two principal divisions: Technegas and Molecular Imaging. Through its Technegas segment, Cyclopharm supplies diagnostic apparatus and accompanying consumables critical for clinicians in the identification of pulmonary embolisms, alongside distributing third-party offerings to the broader diagnostic imaging sector. Conversely, the Molecular Imaging division provides advanced radiopharmaceutical agents essential for medical practitioners diagnosing conditions such as cancer, various neurological disorders, and cardiac diseases. Cyclopharm primarily serves nuclear medicine departments. Established in 1986, the company's corporate headquarters are located in Kingsgrove, Australia.
CYC Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(92.31% Upside)
Technical Analysis
Compumedics Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
OncoSil Medical Ltd
―
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―